This workshop offers a uniquely data-driven and translational perspective on co-stimulation. Drawing on clinical-stage learnings from haematologic indications, unpack how co-stimulation behaves in real patients, how early preclinical signals map to later clinical outcomes, and how these insights can critically inform the strategic design and next steps for T-cell engagers targeting solid tumors.

This workshop will cover:

• What Clinical Data Tells Us: Key findings from Roche’s haematology programs: how co-stimulatory domains improved efficacy, durability, and T-cell fitness in the clinic
• Bridging Preclinical → Clinical: How different domains signal in preclinical models, which readouts most reliably predict clinical behaviour, and which don’t
• Co-Stimulation in Solid Tumours: Why success in the haem space hasn’t yet translated to solid tumours, and what biological & microenvironmental barriers must be engineered around
• Domain & Biology Optimization: Comparative assessment of co-stimulatory signals (e.g., CD28 vs CD137) and how their biology may inform domain prioritisation specifically for solid tumour contexts
• Strategic Design Framework: Leveraging clinical learnings and key assumptions to define the strategic and next-step approaches for solid tumour co-stimulation design.